-
Track & Monitor
Venture Capital Investment Trends in Pharma - Q2 2026
This report analyzes the venture capital (VC) investment activity in Q2 2026 in the Pharma sector.
-
Sector Analysis
Three Possible Scenarios for MFN Implementation in the US: What Can Pharma Expect and What Are the Possible Strategies to Protect Revenue
Just over a year ago, US President Donald Trump signaled his intent to introduce international reference pricing (IRP) for medicines in the US through the May 2025 Most Favored Nation (MFN) executive order. Based on GlobalData's extensive repository of IRP knowledge and daily tracking of pricing and reimbursement developments around the world, in this strategic report GlobalData explores alternative scenarios for MFN implementation and what these mean for the pharmaceutical industry, with a particular focus on how to protect pharma...
-
Sector Analysis
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape
Why Does the FSGS Therapeutics Market Matter? Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease characterized by scarring of the glomeruli and can lead to progressive kidney dysfunction. The treatment landscape is undergoing a significant shift as disease-specific therapies emerge alongside established supportive and off-label treatment approaches. GlobalData’s Focal Segmental Glomerulosclerosis (FSGS): Market View provides a data-driven assessment of the current and future competitive landscape, combining Pharma Intelligence Center data with in-house analyst expertise. In 2025, there were 37,049...
-
Consumer Insights
Industry Insights: How Dietary Supplements Have Evolved Beyond Traditional Health Management
This report highlights the shift in consumer preferences from traditional health supplements to modern formats designed to address specific health needs. As people become more health-conscious, they are increasingly seeking tailored, localized products that support longevity and overall vitality. Growing interest in these contemporary supplements is largely fueled by online marketing and easier access to health information through social media. The report explores consumer interest in nootropics, nutricosmetics, and cellular health supplements. As health and wellness become a higher priority...
-
Sector Analysis
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in IgA Nephropathy (Berger’s Disease) Therapeutics. • In 2025, there were 102,155 incident cases of Berger's disease in the 16 countries covered in GlobalData’s epidemiology forecast. • Berger's disease is primarily managed with blood pressure medication like ACE inhibitors or ARBs to protect the kidneys. For high-risk patients, corticosteroids and newer targeted therapies are also available to slow the disease's progression. • The Berger's disease pipeline holds...
-
Sector Analysis
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future Competitive Landscape
Why Does the Global Reflux Esophagitis Therapeutics Market Matter? Reflux esophagitis and gastroesophageal reflux disease (GERD) represent a significant global therapeutic market, with treatment typically involving lifestyle modifications, pharmacological therapies, and, in selected cases, surgical or endoscopic interventions. GlobalData’s Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Market View provides a data-driven assessment of the current and future competitive landscape, combining Pharma Intelligence Center data with analyst expertise. In 2025, there were 308.98 million 12-month total diagnosed prevalent cases of GERD across...
-
Sector Analysis
Postpartum Depression (PPD): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Postpartum Depression (PPD) Therapeutics. In 2025, there were 10.89 million prevalent cases of PPD across the 16 countries covered in GlobalData’s epidemiology forecast. PPD is typically managed with psychotherapy (CBT or interpersonal therapy) and antidepressants, most commonly SSRIs, tailored to breastfeeding considerations and patient preferences, alongside practical supports such as sleep and family assistance. For moderate-to-severe illness, faster-acting neuroactive steroid treatments include IV brexanolone (a 60-hour...
-
Sector Analysis
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
Why Does Hepatocellular Carcinoma Epidemiology Matter? Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for approximately 90% of primary liver cancers. Understanding the size and characteristics of the HCC patient population is important for assessing disease burden and planning therapeutic strategies. HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide. This epidemiology model provides a 10-year forecast of diagnosed incident cases, five-year diagnosed prevalent cases, and all-time diagnosed prevalent...
-
Sector Analysis
Overweight and Obesity: Epidemiology Report and Forecast to 2035
Why Does Overweight and Obesity Epidemiology Matter? Overweight and obesity are major health conditions associated with excess body fat, metabolic dysfunction, chronic inflammation, and comorbidities including diabetes and cardiovascular disease. Understanding the size and characteristics of these populations is essential for healthcare and life sciences companies developing products and commercial strategies. This report provides a comprehensive epidemiological assessment across the seven major markets (7MM), covering the US, France, Germany, Italy, Spain, the UK, and Japan. You can use this report...
-
Sector Analysis
Against the Clock: the Bundibugyo Ebola Outbreak
Research into new Ebola vaccines and therapeutics, ranging from prophylaxis to post-exposure prophylaxis treatment candidates, are being fast-tracked, using similar mechanisms to fast-tracked COVID-19 trials. Even so, there are legitimate concerns that the Bundibugyo strain of the Ebola virus is moving faster than the response of technology developers, regulators, governments, and international organizations.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.